The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | Updated POLLUX results for early relapsed myeloma patients
Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, updates us at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, on the results from the POLLUX trial (NCT02076009). Dr Usmani describes the overall median survival, median progression-free survival, and measurable residual disease data in early relapsed myeloma patients receiving daratumumab, lenalidomide and dexamethasone treatment.
